
Insights Lab
Latest insights, research and strategies to help support innovators to achieve real outcomes.
Latest Insights
Australia has long grappled with the so-called "commercialisation gap”, a persistent disconnect between the quality of our research and the extent to which it’s translated into economic impact. A new report from CSIRO provides an up to date picture of what outcomes can (and can’t) be expected from government programs designed to support it.
From the $22.7B Future Made in Australia agenda to the promise of new funding for innovation, manufacturing, and SMEs, the re-election of the Albanese Labor government is expected to see a raft of programs and policies implemented to support Australian businesses. We've summarised what the next term has in store with a focus on the already announced support for its national industry priorities, as well as policies and programs that might further R&D and innovation.
The R&D Tax Incentive expressly excludes certain activities from qualifying as ‘core R&D activities’. However, these excluded activities can still qualify as supporting R&D activities if a sufficient nexus to the conduct of the core R&D activity can be established. A recent Administrative Review Tribunal ruling has helpfully clarified that medical and health related research, even when involving behavioural aspects, is not excluded and is capable of being registered as an eligible core R&D activity.
The end of the financial year is once again here, and it brings with it some important considerations. If you’re planning to lodge an R&D Tax Incentive claim for FY25, now is the time to check in with your advisors and ensure you're across a few key issues before 30 June.
The Export Market Development Grants (EMDG) Program continues to empower Australian SMEs by providing 50:50 matched funding for export promotion and marketing development. Austrade has recently released data summarising key trends from previous completed rounds of the program highlighting how EMDG funding has helped Australian businesses expand internationally.
Intellect Labs’ R&D Tax Facts is a summary of important developments in the world of the R&D Tax Incentive (R&DTI) over the last 3 months.
An important reminder for Australian businesses with a 30 June year financial year that the deadline for lodging your 2023-24 R&D Tax Incentive (RDTI) Application is fast-approaching.
Insights into Medical Research Future Fund (MRFF) grant allocation, success rates, and key initiatives over time. As MRFF funding continues to shape the future of health research in Australia, understanding these trends can help applicants refine their strategies and improve their chances of success.
With the Queensland State Government election fast-approaching, it’s important that any Queensland businesses that are considering applying for state government funding understand what impact the election will have on grant programs. We’ve summarised our analysis of the impact that elections can have on the grant funding landscape, with a particular focus on the Queensland State Government election in October.
The Medical Research Future Fund (MRFF) is a major source of health research funding in Australia, providing opportunities for both researchers and companies. The MRFF publishes funding rounds in advance, giving applicants reasonable notice to prepare. We have prepared an overview of upcoming grant opportunities, eligibility, and how Intellect Labs can support your submission.
Clinical trials have long been viewed favourably under the R&D Tax Incentive Program. To recognise this, the program offers an efficient registration process for trials registered with the Therapeutic Goods Administration, reducing the administrative burden for biotech companies. This streamlined approach, along with support through Advance Overseas Findings (AOF), empowers Australian biotech firms to innovate and lead on the global stage.
The Overseas Finding process is a crucial component of the Research & Development Tax Incentive (RDTI) in Australia, enabling companies to access a tax benefit for overseas activities that relate to an Australian R&D program. This guide explores the Overseas Finding process, the key conditions for eligibility, and recent ATO concerns as outlined in taxpayer alerts. We also highlight a successful case study with a cyber security innovator, Internet 2.0, to illustrate effective strategies for securing an Overseas Finding.
Featured Posts
Featured Grants
A federal government initiative with $150 million of matched funding available for this first round.
Case Studies
Internet 2.0’s case illustrates how a well-prepared Overseas Funding application can lead to significant financial support and increased investor confidence. It underscores the importance of strategic planning and thorough documentation in the R&D tax incentive process.
With the help of the R&D Tax Incentive (‘RDTI’) program, Dataweavers is investing in R&D to deliver innovative solutions for deploying complex enterprise marketing technology and Digital Experience Platforms (DXPs) in the public cloud.
Ridley Corporation is accessing the R&D Tax Incentive (‘RDTI’) to help them drive innovation in Australian agriculture by providing advanced, sustainable animal nutrition solutions that assist farmers to enhance animal health and productivity while reducing environmental impact.
A $5m grant from the Medical Research Future Fund (MRFF) will help Southern RNA combine its new manufacturing capability with the Queensland research community to create an end-to-end mRNA translation ecosystem.
Start-up medical device company Neurode is accessing the Federal Government’s flagship innovation program, the R&D Tax Incentive (‘RDTI’), to improve quality of life for people diagnosed with ADHD.
Great Wrap is on a mission to remove the 150,000 tonnes of plastic stretch wrap sent to Australia’s landfill each year. A $535,000 grant from the Advanced Manufacturing Growth Centre will help them to do just that.
$2.57m from the Federal Government’s flagship manufacturing program will help Cyclowest fast-track production of next generation cancer treatments.